ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.70
+0.01 (+0.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.69
Open2.69
Bid0.00 x 3000
Ask2.95 x 4000
Day's Range2.63 - 2.70
52 Week Range1.58 - 4.09
Volume457,817
Avg. Volume736,877
Market Cap423.43M
Beta-0.41
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.92
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of ATRS earnings conference call or presentation 8-May-18 12:30pm GMT

    Q1 2018 Antares Pharma Inc Earnings Call

  • ACCESSWIRE12 days ago

    Complimentary Technical Snapshots on Akers Biosciences and Two More Medical Supplies Stocks

    Stock Research Monitor: ATRS and BAX LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on AKER sign up now at www.wallstequities.com/registration . On Tuesday, July 03, 2018, US ...

  • Is Antares Pharma Inc’s (NASDAQ:ATRS) Balance Sheet A Threat To Its Future?
    Simply Wall St.22 days ago

    Is Antares Pharma Inc’s (NASDAQ:ATRS) Balance Sheet A Threat To Its Future?

    While small-cap stocks, such as Antares Pharma Inc (NASDAQ:ATRS) with its market cap of US$421.86m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • ACCESSWIRElast month

    Akers Biosciences and Three Additional Stocks Under Scanner in the Medical Supplies Space

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on AKER sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Medical Instruments & Supplies equities: Akers Biosciences Inc. (NASDAQ: AKER), Antares Pharma Inc. (NASDAQ: ATRS), Baxter International Inc. (NYSE: BAX), and Becton, Dickinson and Co. (NYSE: BDX).

  • GlobeNewswire2 months ago

    Antares Pharma Announces Receipt of Third Installment From Sale of ZOMAJET™ Needle-Free Delivery System

    Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injection technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva) and AMAG Pharmaceuticals, Inc.  Antares Pharma’s proprietary products include OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company has developed an investigational new drug for testosterone replacement therapy called XYOSTED™, currently under active review at the FDA with a PDUFA date of September 29, 2018.

  • GlobeNewswire2 months ago

    Antares Pharma to Present at the Jefferies 2018 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 9:00 a.m. Eastern Time. Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injection technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva) and AMAG Pharmaceuticals, Inc.  Antares Pharma’s proprietary products include OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • ACCESSWIRE2 months ago

    Free Post Earnings Research Report: ResMed’s Revenue Jumped 15%; Adjusted EPS Surged 30%

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free earnings report on ResMed Inc. (NYSE: RMD), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RMD. ResMed reported its Q3 FY18 operating and financial results on April 26, 2018. Active-Investors.com is currently working on the research report for Antares Pharma, Inc. (NASDAQ: ATRS), which also belongs to the Healthcare sector as the Company ResMed.

  • Zacks Small Cap Research2 months ago

    ATRS: Makena Maturing Quickly, Providing 1Q:18 Boost

    A strong showing by Makena auto-injectors in was behind the better than expected revenue increase. Recent successes include the regulatory approval of Makena, progress on the sale of Zomajet and continued interaction with the FDA to get Xyosted across the finish line. The Auto/Pen Injector Devices segment was the standout in the quarter due to contributions from Makena.

  • Associated Press2 months ago

    Antares Pharma: 1Q Earnings Snapshot

    The Ewing, New Jersey-based company said it had a loss of 4 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Antares Pharma Reports First Quarter 2018 Operating and Financial Results

    EWING, N.J., May 08, 2018-- Antares Pharma, Inc. today reported operating and financial results for the first quarter ended March 31, 2018. The Company reported revenue of $12.7 million and a net loss ...

  • GlobeNewswire2 months ago

    Antares Pharma to Present at the Deutsche Bank Securities, Inc. 43rd Annual Health Care Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:00 am Eastern Time. Antares Pharma is a specialty pharmaceutical company primarily focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies.  The Company develops and manufactures, for itself or with partners, novel therapeutic products using its advanced drug delivery technology to enhance the existing drug compounds and delivery methods. The Company has a portfolio of proprietary and partnered products, including approved commercial products and several partnered product candidates in advanced stages of development.  The Company has formed significant strategic alliances with Teva Pharmaceutical Industries, Ltd. (“Teva”) and AMAG Pharmaceuticals, Inc. (“AMAG”), and has multiple ongoing internal and partnered product development programs.

  • GlobeNewswire3 months ago

    Antares Pharma to Report First Quarter 2018 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its first quarter 2018 financial results and recent operating progress before the market opens on Tuesday, May 8, 2018.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on May 8, 2018 to discuss the results. Interested parties may participate in the conference call by dialing 1-800-289-0438 or 1-323-794-2423 and entering access code 1980247.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Tuesday, May 8, 2018, through 11:30 a.m. ET on Thursday, June 7, 2018 by dialing 1-888-203-1112 or 1-719-457-0820 and entering the access code 1980247.  An audio webcast and archive of the conference call will also be available under the “For Investors” section of the Antares Website at www.antarespharma.com.

  • Zacks Small Cap Research4 months ago

    ATRS: Xyosted Regulatory Update

    By John Vandermosten, CFA NASDAQ:ATRS Antares Pharma (NASDAQ:ATRS) held its Type A meeting with the FDA on February 21, 2018, that addressed the complete response letter (CRL) for Xyosted which was received ...

  • Zacks Small Cap Research4 months ago

    ATRS: Multiple New Launches Fire Up 2018

    Total revenues for 2017 were $54.5 million, up from $49.5 million in 2016.  Otrexup was a standout in the year and the quarter rising 18.5% and 17.4% respectively and comprising a third of total sales.  Fourth quarter sales were $4.8 million, compared to $4.6 million in 3Q:17 and $4.1 million in 4Q:16. Gross profit for the year was $27.1 million which represents a margin of 49.6%, while fourth quarter levels were $6.9 million generating an associated margin of 49.4%.  Full year product sales margin was 46.5%, up sharply from 2016’s 36.4%.  Fourth quarter product sales margins were even stronger at 48.7%, compared the 4Q:16 levels at 25.2%.  Development revenue gross margins were down compared to the prior year, coming in at 49.0% for full year 2017 and are dependent on product mix.  Contributions from Otrexup and higher licensing revenues helped drive the increase over prior year levels.  R&D declined by 38% versus the prior year as efforts related to Xyosted and other programs tapered off and as the company lapped a $2 million NDA submission fee paid in 2016 that did not recur.  SG&A was up 15% for the full year and up 19% in the fourth quarter on a year over year basis reflecting the preparation Antares had done for the Xyosted approval.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ATRS earnings conference call or presentation 13-Mar-18 12:30pm GMT

    Q4 2017 Antares Pharma Inc Earnings Call

  • Associated Press4 months ago

    Antares Pharma reports 4Q loss

    On a per-share basis, the Ewing, New Jersey-based company said it had a loss of 2 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • ACCESSWIRE4 months ago

    Antares Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Antares Pharma, Inc. (NASDAQ: ATRS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 8:30 AM Eastern Time. ...